Published: 9 April 2022
Author(s): Charlotte C. van Ruiten, Anne C. Hesp, Daniël H. van Raalte
Issue: June 2022
Section: Review Article

Diabetic kidney disease (DKD) is a common complication of diabetes, affecting ∼ 40% of patients with type 2 diabetes (T2D) [1]. DKD is characterized by increased urinary albumin excretion and/or impaired glomerular filtration rate (GFR) [2]. DKD is a multifactorial disease, and obesity, systemic and glomerular hypertension, dyslipidemia, and smoking are well-known contributing factors on top of hyperglycemia. Current therapies to prevent or slow the progression of DKD are based on reducing these kidney risk factors, such as blood glucose and blood pressure control, the latter by blockers of the renin angiotensin aldosterone system (RAAS) [3].


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.